SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:SCYX
- CUSIP: N/A
- Web: www.scynexis.com
Capitalization:- Market Cap: $56.24 million
- Outstanding Shares: 26,722,000
Average Prices:- 50 Day Moving Avg: $1.84
- 200 Day Moving Avg: $2.08
- 52 Week Range: $1.52 - $5.51
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.74
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $256,999.00
- Price / Sales: 253.70
- Book Value: $1.20 per share
- Price / Book: 2.03
Profitability:- EBIDTA: ($25,040,000.00)
- Net Margins: -9,648.47%
- Return on Equity: -64.04%
- Return on Assets: -37.19%
Debt:- Debt-to-Equity Ratio: 0.41%
- Current Ratio: 10.89%
- Quick Ratio: 10.89%
Misc:- Average Volume: 256,166 shs.
- Beta: 0.32
- Short Ratio: 12.29
Frequently Asked Questions for SCYNEXIS (NASDAQ:SCYX)
What is SCYNEXIS's stock symbol?
SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."
How were SCYNEXIS's earnings last quarter?
SCYNEXIS, Inc. (NASDAQ:SCYX) announced its quarterly earnings results on Monday, August, 8th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.04. The company had revenue of $0.06 million for the quarter. SCYNEXIS had a negative net margin of 9,648.47% and a negative return on equity of 64.04%. View SCYNEXIS's Earnings History.
Where is SCYNEXIS's stock going? Where will SCYNEXIS's stock price be in 2017?
8 brokerages have issued 12-month price targets for SCYNEXIS's stock. Their forecasts range from $7.00 to $16.00. On average, they anticipate SCYNEXIS's share price to reach $11.25 in the next twelve months. View Analyst Ratings for SCYNEXIS.
Who are some of SCYNEXIS's key competitors?
Some companies that are related to SCYNEXIS include Aralez Pharmaceuticals (ARLZ), Diurnal Group PLC (DNL), BioLife Solutions (BLFS), Concordia International Corp. (CXRX), Evoke Pharma (EVOK), Juniper Pharmaceuticals (JNP), Amryt Pharma PLC (AMYT), Histogenics Corporation (HSGX), Pernix Therapeutics Holdings (PTX), Intellipharmaceutics International (IPCI), Cellectar Biosciences (CLRB), Apricus Biosciences (APRI), Eyegate Pharmaceuticals (EYEG), Venture Life Group PLC (VLG), Immune Pharmaceuticals (IMNP), Neuralstem (CUR), Galena Biopharma (GALE) and Aegerion Pharmaceuticals (AEGR).
Who are SCYNEXIS's key executives?
SCYNEXIS's management team includes the folowing people:
- Pamela J. Kirby Ph.D., Chairman of the Board
- Marco Taglietti M.D., President, Chief Executive Officer, Director
- Eric S. Francois, Chief Financial Officer
- David Angulo M.D., Chief Medical Officer
- Laurent Arthaud, Director
- Steven C. Gilman Ph.D., Director
- Ann F. Hanham Ph.D., Director
- David C. Hastings, Director
- Patrick J. Langlois Ph.D., Director
Who owns SCYNEXIS stock?
SCYNEXIS's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Federated Investors Inc. PA (16.31%), FMR LLC (3.61%), Vanguard Group Inc. (3.37%), DAFNA Capital Management LLC (1.96%), National Asset Management Inc. (1.19%) and Private Advisor Group LLC (0.78%). Company insiders that own SCYNEXIS stock include Ann Hanham, David C Hastings, Eric Francois, Gonzalez David Angulo, Guy Macdonald, Marco Taglietti and Patrick Machado. View Institutional Ownership Trends for SCYNEXIS.
Who sold SCYNEXIS stock? Who is selling SCYNEXIS stock?
Who bought SCYNEXIS stock? Who is buying SCYNEXIS stock?
SCYNEXIS's stock was acquired by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, National Asset Management Inc., DAFNA Capital Management LLC, Vanguard Group Inc. and GSA Capital Partners LLP. Company insiders that have bought SCYNEXIS stock in the last two years include Ann Hanham, David C Hastings, Eric Francois, Gonzalez David Angulo, Guy Macdonald, Marco Taglietti and Patrick Machado. View Insider Buying and Selling for SCYNEXIS.
How do I buy SCYNEXIS stock?
Shares of SCYNEXIS can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SCYNEXIS's stock price today?
One share of SCYNEXIS stock can currently be purchased for approximately $2.44.
MarketBeat Community Rating for SCYNEXIS (NASDAQ SCYX)MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for SCYNEXIS (NASDAQ:SCYX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 6 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $11.25 (361.07% upside) |
Analysts' Ratings History for SCYNEXIS (NASDAQ:SCYX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/16/2017 | HC Wainwright | Set Price Target | Buy | $14.00 | High |  |
| 8/7/2017 | Roth Capital | Set Price Target | Buy | $9.00 | Medium | |
| 5/30/2017 | Aegis | Reiterated Rating | Buy | | Medium | |
| 5/9/2017 | Needham & Company LLC | Downgrade | Buy -> Hold | | High | |
| 3/14/2017 | Guggenheim | Reiterated Rating | Buy | $15.00 | High | |
| 3/3/2017 | Royal Bank Of Canada | Reiterated Rating | Outperform | $15.00 -> $11.00 | N/A | |
| 10/7/2016 | WBB Securities | Upgrade | Buy -> Strong-Buy | $8.00 | N/A | |
| 10/3/2016 | Brean Capital | Initiated Coverage | Buy | $16.00 | N/A | |
| 6/9/2016 | Canaccord Genuity | Reiterated Rating | Buy | | N/A | |
(Data available from 9/21/2015 forward)
Earnings History for SCYNEXIS (NASDAQ:SCYX)Earnings History by Quarter for SCYNEXIS (NASDAQ SCYX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/8/2016 | Q216 | ($0.52) | ($0.56) | | $0.06 million | View | N/A | |
| 5/9/2016 | Q116 | ($0.63) | ($0.52) | | $0.06 million | View | N/A | |
| 11/13/2015 | Q315 | ($0.62) | ($0.60) | | $0.06 million | View | N/A | |
| 5/15/2015 | Q115 | ($0.43) | ($0.75) | $4.20 million | $2.31 million | View | N/A | |
| 3/30/2015 | | ($0.71) | ($0.45) | | $5.30 million | View | N/A | |
| 11/13/2014 | | ($0.53) | ($0.45) | | $4.38 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for SCYNEXIS (NASDAQ:SCYX)Current Year EPS Consensus Estimate: $-1.21 EPS
Next Year EPS Consensus Estimate: $-1.4 EPS
Dividend History for SCYNEXIS (NASDAQ:SCYX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for SCYNEXIS (NASDAQ:SCYX)Insider Ownership Percentage: 3.91%
Institutional Ownership Percentage: 36.75%
Insider Trades by Quarter for SCYNEXIS (NASDAQ:SCYX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/23/2017 | Marco Taglietti | CEO | Buy | 5,000 | $1.85 | $9,250.00 | |
| 8/15/2017 | Marco Taglietti | CEO | Buy | 10,000 | $1.61 | $16,100.00 | |
| 8/11/2017 | Gonzalez David Angulo | Insider | Buy | 10,000 | $1.55 | $15,500.00 | |
| 6/21/2017 | David C Hastings | Director | Buy | 20,000 | $1.75 | $35,000.00 | |
| 5/12/2017 | Gonzalez David Angulo | Insider | Buy | 15,000 | $1.70 | $25,500.00 | |
| 5/12/2017 | Marco Taglietti | CEO | Buy | 25,000 | $1.69 | $42,250.00 | |
| 12/21/2016 | Marco Taglietti | CEO | Buy | 25,000 | $3.30 | $82,500.00 | |
| 12/16/2016 | Gonzalez David Angulo | Insider | Buy | 4,000 | $3.25 | $13,000.00 | |
| 9/15/2016 | Patrick Machado | Director | Buy | 40,000 | $2.94 | $117,600.00 | |
| 6/30/2016 | Gonzalez David Angulo | Insider | Buy | 36,950 | $2.22 | $82,029.00 | |
| 6/24/2016 | Eric Francois | CFO | Buy | 15,000 | $2.39 | $35,850.00 | |
| 6/24/2016 | Guy Macdonald | Director | Buy | 40,000 | $2.39 | $95,600.00 | |
| 6/24/2016 | Marco Taglietti | CEO | Buy | 100,000 | $2.39 | $239,000.00 | |
| 5/25/2016 | Ann Hanham | Director | Buy | 4,225 | $3.64 | $15,379.00 | |
| 5/25/2016 | Marco Taglietti | CEO | Buy | 5,754 | $3.26 | $18,758.04 | |
| 5/24/2016 | Marco Taglietti | CEO | Buy | 5,500 | $3.37 | $18,535.00 | |
| 5/23/2016 | Marco Taglietti | CEO | Buy | 7,500 | $3.14 | $23,550.00 | |
| 5/19/2016 | Marco Taglietti | CEO | Buy | 6,000 | $3.07 | $18,420.00 | |
| 11/24/2015 | Marco Taglietti | CEO | Buy | 22,733 | $6.79 | $154,357.07 | |
| 8/31/2015 | Marco Taglietti | CEO | Buy | 25,000 | $7.82 | $195,500.00 | |
| 8/28/2015 | Marco Taglietti | CEO | Buy | 2,267 | $7.08 | $16,050.36 | |
| 8/26/2015 | Marco Taglietti | CEO | Buy | 50,000 | $7.07 | $353,500.00 | |
| 5/7/2014 | Jean-Yves Nothias | Director | Buy | 50,000 | $10.00 | $500,000.00 | |
| 5/7/2014 | Ventech Capital Ii | Major Shareholder | Buy | 28,000 | $10.00 | $280,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for SCYNEXIS (NASDAQ:SCYX)
Latest Headlines for SCYNEXIS (NASDAQ:SCYX)
| Source: |
|
| Date | Headline |
|---|
 | SCYNEXIS (SCYX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 9:51 AM |
 | What Does SCYNEXIS Inc’s (SCYX) Share Price Indicate?
finance.yahoo.com - September 14 at 9:51 AM |
 | SCYNEXIS, Inc. (SCYX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - September 12 at 9:32 AM |
| SCYNEXIS, Inc. (SCYX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - September 7 at 8:20 AM |
| SCYNEXIS, Inc. (SCYX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 6 at 6:46 PM |
| SCYNEXIS, Inc. (SCYX) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - September 6 at 7:20 AM |
| ETFs with exposure to SCYNEXIS, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 8:32 AM |
| ETFs with exposure to SCYNEXIS, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 8:32 AM |
| SCYNEXIS to Present at Upcoming Investor Conferences
finance.yahoo.com - August 31 at 9:49 AM |
| SCYNEXIS, Inc. (SCYX) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - August 29 at 10:21 AM |
| SCYNEXIS, Inc. (SCYX) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 26 at 6:22 AM |
| SCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 11:23 AM |
| Scynexis Q2 - Steady As She Goes - Seeking Alpha
seekingalpha.com - August 23 at 11:22 AM |
| SCYNEXIS, Inc. (SCYX) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - August 22 at 10:36 PM |
| SCYNEXIS, Inc. (SCYX) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - August 19 at 9:12 AM |
| Insider Buying: SCYNEXIS, Inc. (SCYX) CEO Buys 10,000 Shares of Stock
www.americanbankingnews.com - August 17 at 10:24 AM |
| SCYNEXIS, Inc. (SCYX) Given a $14.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - August 16 at 8:02 AM |
 | “THINK FUNGUS” - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease ... - GlobeNewswire (press release)
globenewswire.com - August 15 at 4:26 PM |
| “THINK FUNGUS” - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease Control and Prevention (CDC)
finance.yahoo.com - August 15 at 4:26 PM |
| SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis ... - GlobeNewswire (press release)
globenewswire.com - August 15 at 6:49 AM |
| SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual Meeting
finance.yahoo.com - August 15 at 6:49 AM |
| SCYNEXIS, Inc. (NASDAQ:SCYX) Insider Gonzalez David Angulo Purchases 10,000 Shares
www.americanbankingnews.com - August 15 at 12:16 AM |
| SCYNEXIS, Inc. (SCYX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 12 at 6:38 PM |
| SCYNEXIS Reports Second Quarter 2017 Financial Results and ... - GlobeNewswire (press release)
globenewswire.com - August 9 at 7:19 AM |
| SCYNEXIS Reports Second Quarter 2017 Financial Results and Provides Company Update
finance.yahoo.com - August 9 at 7:19 AM |
| Roth Capital Analysts Give SCYNEXIS Inc (NASDAQ:SCYX) a $9.00 Price Target
www.americanbankingnews.com - August 7 at 6:20 PM |
| SCYNEXIS to Present at the Canaccord Genuity Growth Conference - GlobeNewswire (press release)
globenewswire.com - August 7 at 3:29 PM |
 | SCYNEXIS to Present at the Canaccord Genuity Growth Conference
feeds.benzinga.com - August 7 at 10:25 AM |
| SCYNEXIS Announces Initiation of Dosing in Phase 2 Study ... - GlobeNewswire (press release)
globenewswire.com - August 4 at 8:01 AM |
| SCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis
finance.yahoo.com - August 4 at 8:01 AM |
| SCYNEXIS, Inc. (SCYX) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - August 2 at 8:32 AM |
| SCYNEXIS, Inc. (SCYX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 18 at 6:56 PM |
| SCYNEXIS Inc (NASDAQ:SCYX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - July 14 at 11:40 PM |
| SCYNEXIS, Inc. (SCYX) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - July 12 at 12:44 PM |
| SCYNEXIS, Inc. (SCYX) Coverage Initiated at Roth Capital
www.americanbankingnews.com - July 10 at 9:02 PM |
| SCYNEXIS, Inc. (SCYX) Expected to Post Earnings of -$0.41 Per Share
www.americanbankingnews.com - June 27 at 4:08 PM |
| SCYNEXIS, Inc. (SCYX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 23 at 5:08 PM |
| SCYNEXIS, Inc. (SCYX) Director David C. Hastings Acquires 20,000 Shares
www.americanbankingnews.com - June 22 at 10:56 AM |
 | Scynexis (SCYX) Publishes Data on In Vitro Activity of SCYNEXIS ... - StreetInsider.com
www.streetinsider.com - June 15 at 4:32 PM |
| New Study Further Demonstrates In Vitro Activity of SCYNEXIS’ Lead Anti-Infective Candidate, SCY-078, Against Drug-Resistant Candida Fungal Strains
finance.yahoo.com - June 15 at 4:32 PM |
| ETFs with exposure to SCYNEXIS, Inc. : June 14, 2017
finance.yahoo.com - June 15 at 12:26 AM |
 | SCYNEXIS, Inc. to Participate in the 2017 BIO International Convention - Nasdaq
www.nasdaq.com - June 13 at 10:46 AM |
| SCYNEXIS, Inc. to Participate in the 2017 BIO International Convention
finance.yahoo.com - June 13 at 10:46 AM |
| Zacks Investment Research Upgrades SCYNEXIS Inc (SCYX) to "Buy"
www.americanbankingnews.com - June 10 at 12:32 PM |
| SCYNEXIS Inc (SCYX) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - June 8 at 7:24 AM |
| Eight Presentations at ASM Microbe 2017 Further Highlight the Strong Antifungal Effect and Promising Safety Profile of Lead Anti-Infective Candidate SCY-078
finance.yahoo.com - June 5 at 3:34 PM |
| SCYNEXIS Inc (SCYX) Stock Rating Reaffirmed by Aegis
www.americanbankingnews.com - June 3 at 7:44 AM |
| Analysts Expect SCYNEXIS Inc (SCYX) Will Post Earnings of -$0.41 Per Share
www.americanbankingnews.com - June 1 at 2:46 PM |
| SCYNEXIS Inc (SCYX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 29 at 4:56 PM |
| Eight SCY-078 Data Presentations at ASM Microbe 2017 Confirm Potential of SCYNEXIS’ Lead Agent to Combat Serious and Life-threatening Fungal Infections
finance.yahoo.com - May 24 at 9:34 AM |
SCYNEXIS (SCYX) Chart for Thursday, September, 21, 2017
